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Introduction {#sec005}
============

Acute kidney injury (AKI) affects 20 to 50% of intensive care unit (ICU) patients, and it is associated with high mortality, increased ICU length of stay and greater hospitalization cost \[[@pone.0226325.ref001]--[@pone.0226325.ref005]\]. When renal replacement therapy (RRT) is used, mortality rates can reach up to 80% \[[@pone.0226325.ref002],[@pone.0226325.ref006]\].

It is widely accepted that AKI characteristics are different in developed and developing countries due to contrasting socioeconomic patterns, government health expenditures, heath service infrastructure and AKI etiology \[[@pone.0226325.ref007]\].

Although the vast majority of the global population lives in developing countries, most of the epidemiological data from ICU patients with AKI comes from developed countries. Comparisons of these two different settings are scarce. A multicenter prospective study found higher mortality for ICU AKI patients in developing countries \[[@pone.0226325.ref008]\], which might be related to an inadequate number of ICU beds in relation to population size and the difficulty of health care access, among other reasons. To determine whether the outcomes in these populations are comparable, it is necessary to evaluate whether there are differences in patient characteristics as well as the methodological aspects among the analyzed studies.

This systematic review covers methodological aspects, including AKI and reference serum creatinine definitions, as well as the main characteristics and outcomes of ICU AKI patients from studies in developed and developing countries. We aim to determine whether epidemiological comparisons between these two country categories are appropriate with the available data and to estimate their AKI incidence using meta-analysis.

Material and methods {#sec006}
====================

Database search {#sec007}
---------------

This systematic review was conducted using the recommendations of the *"Cochrane Handbook for Systematic Reviews of Interventions"* \[[@pone.0226325.ref009]\] ([Fig 1](#pone.0226325.g001){ref-type="fig"}). A systematic electronic search was performed to identify all original studies which might include acute kidney injury patients in intensive care units published from 2005 until 2015, including the keyword terms: "acute kidney injury", "acute kidney failure", "acute kidney insufficiency", "acute renal injury", "acute renal failure", "acute renal insufficiency", "intensive care units", "critical ill patient and critical ill". We accessed the PubMed, CENTRAL (Cochrane Controlled Register of Trials), LILACS (Latin American and Caribbean Health Sciences Library), and IBECs (Spanish Bibliographical Index of Health Sciences) databases. The search strategies for each database can be found in [S1 File](#pone.0226325.s001){ref-type="supplementary-material"}. This search was last updated on July 31, 2015, and the language was limited to English, Spanish, French, Italian and Portuguese. The manuscripts were manually analyzed in order to find additional references. There was no blinding in relation to the author, place of publication, or journal.

![Flowchart of study selection.](pone.0226325.g001){#pone.0226325.g001}

The studies were classified into two groups: those from developed and those from developing countries, and they were assigned group membership based on the United Nations classification.

Study selection {#sec008}
---------------

An initial eligibility screen of all retrieved titles and abstracts was conducted, and only studies reporting AKI in intensive care units in the 10-year surveyed period were selected for further review. Full-text papers were obtained for inspection of each study that potentially fulfilled the inclusion criteria on the basis of title and/or abstract. The following specific criteria were used for final selection: only studies with adult patients and those with reported epidemiological data. Duplicate articles were identified and eliminated using the Endnoteweb \[[@pone.0226325.ref010]\] software tool.

The final group of manuscripts was selected by the main author and reviewed by a coauthor. Discordances were solved by consensus using the predefined inclusion and exclusion criteria in accordance with the recommendations of the *"Cochrane Handbook for Systematic Reviews of Interventions*" \[[@pone.0226325.ref009]\]. When necessary, a final decision was achieved by consulting a third coauthor.

Data collection process {#sec009}
-----------------------

Two authors performed independent data extraction using standardized data extraction forms.

The following data were retrieved:

1.  **Research place and study description**: country, study type, length of data collection, number of ICUs, type of ICU, number of patients.

2.  **AKI characteristics**: incidence, definition, criteria used for definition, timeframe for AKI assessment, percentage of oliguric patients, oliguria definition, reference serum creatinine (SCr) defined as the value used for comparing increased SCr to establish the diagnosis of AKI.

3.  **AKI patient characteristics**: mean age, gender ratio, previous comorbidities, patient source, severity of illness score.

4.  **Outcomes:** length of ICU stay, length of hospital stay, frequency of RRT use, type of RRT, mortality.

Statistical analysis {#sec010}
--------------------

The frequencies of studies were calculated by considering those that assessed the respective data. The number of studies used for each calculation is shown after the presented frequency.

Weighted means and percentages of reported data were estimated using the study population as weight.

The pooled point AKI incidence of developed and developing countries´ studies was estimated for studies that used the RIFLE, AKIN or KDIGO criteria for the AKI definition. All estimates and their 95% confidence intervals (95% CI) were calculated using a random-effects model for descriptive data analysis. Subgroup analyses were conducted with studies grouped by each different criterion for the utilized AKI definition. Heterogeneity and consistency were evaluated using Cochran's Q and the I^2^ statistics, respectively. Funnel plots were used to evaluate publication bias. The analysis was performed in Microsoft Excel, using the step-by-step approach constructed by Neyeloff et al. \[[@pone.0226325.ref011]\] to analyze descriptive data. The pooled AKI incidence of both country groups were compared using the estimated 95% confidence interval.

Results {#sec011}
=======

Of 2,459 potential studies, 1,635 were excluded because they did not assess patients, were duplicates, or had titles and abstracts that were not related to the purpose of this review. Of the remaining 824 studies, 17 were excluded for not meeting the language definitions and 714 were excluded as they did not meet the eligibility criteria. Ninety-two studies were included in the final analysis. One study \[[@pone.0226325.ref008]\] reported data from both developed and developing countries, and its data was reported in both country categories. As a result, the final analysis consisted of 60 studies presenting data from developed countries and 33 studies with data from developing countries ([Fig 1](#pone.0226325.g001){ref-type="fig"} and [Table 1](#pone.0226325.t001){ref-type="table"}). The 92 studies included in the final analysis can be found in [S2 File](#pone.0226325.s002){ref-type="supplementary-material"}.

10.1371/journal.pone.0226325.t001

###### Frequency of studies in developed and developing countries with data reported.
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                                                      Developed countries   Developing countries
  --------------------------------------------------- --------------------- ----------------------
  **Description of studies (n = 93)**                                       
      Retrospective                                   46.7% (28)            42.4% (14)
      Prospective                                     53.3% (32)            57.6% (19)
  **Definition of AKI by**                                                  
      RIFLE                                           34.4% (20)            39.3% (13)
      AKIN                                            37.9% (22)            33.3% (11)
      KDIGO                                           10% (6)               21.2% (7)
      sCr[\*](#t001fn001){ref-type="table-fn"} rise   24.1% (14)            9% (3)
      sCr rise + decreases in     urinary volume      73.2% (41)            78.1% 25
  **Oliguria definition (n = 81)**                    81.6% (49)            97% (32)
  **Reference SCr definition (n = 60)**               68.3% (41)            57.5% (19)
  **Timeframe for AKI diagnosis**                     58.3% (35)            69.6% (23)
  **Frequency of AKI \> 40%**                         54.7% (29)            82.1% (23)
  **AKI etiology described**                          46.6% (28)            66.6% (22)
  **Patient characteristics**                                               
      \> 65 years old                                 40% (22)              12.1% (4)
      Male frequency \> 60%                           59.6% (34)            67.8% (19)
      Comorbidities                                   51.6% (31)            78.7% (26)
      Severity scores                                                       
          APACHE II                                   58.3% (35)            54.5% (18)
          SOFA                                        25% (15)              18.1% (6)
  **Outcomes**                                                              
      Length of ICU stay                              71.6% (43)            69.6% (23)
      Length of hospital stay                         38.3% (23)            21.2% (7)
      RRT \> 30% in AKI patients                      13.3% (8)             30.3% (10)
      Mortality                                       15.9% (7)             56% (14)

\*sCr = serum creatinine

Description of studies {#sec012}
----------------------

### Study design {#sec013}

In both developed and developing countries, the majority of studies were from university hospitals \[91.6% (55/60) and 72.7% (24/33), respectively\] (Tables [2](#pone.0226325.t002){ref-type="table"} and [3](#pone.0226325.t003){ref-type="table"}).

10.1371/journal.pone.0226325.t002

###### Country and study features description---developed countries.
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  Author                          Home country                                    Study type      Length of data collection   Number of ICUs   Type of ICU           Number of Patients
  ------------------------------- ----------------------------------------------- --------------- --------------------------- ---------------- --------------------- --------------------
  Abosaif et al, 2005             England                                         Retrospective   24                          1                Mixed                 247
  Bagshaw et al, 2005             Canada                                          Prospective     36                          3                Mixed                 5,693
  Chawla et al, 2005              USA                                             Prospective     8                           1                Mixed                 194
  Ostermann et al, 2005           England and Germany                             Retrospective   110                         22               Mixed                 41,972
  Ahlstrom et al, 2006            Finland                                         Prospective     11                          2                Mixed                 658
  Herrera-Gutiérrez et al, 2006   Spain                                           Prospective     8                           43               Mixed                 15,714
  Hoste, 2006                     USA                                             Retrospective   12                          7                Mixed                 5,383
  Bagshaw et al, 2007             Australia                                       Prospective     120                         20               Mixed                 91,254
  Cruz et al, 2007                Italy                                           Prospective     3                           19               Mixed                 2,164
  Eachempati et al, 2007          USA                                             Prospective     108                         1                Mixed                 41,972
  Ostermann et al, 2007           England and Germany                             Retrospective   120                         11               Surgery               8,505
  Bagshaw et al, 2008             Australia                                       Retrospective   60                          57               Trauma                124,088
  Bagshaw et al, 2008             Australia                                       Retrospective   60                          57               Mixed                 120,123
  Barrantes et al, 2008           USA                                             Retrospective   12                          1                Mixed                 471
  Lopes et al, 2008               Portugal                                        Retrospective   36                          1                Mixed                 662
  Ostermann et al, 2008           England and Germany                             Retrospective   123                         22               Mixed                 23,303
  Abelha et al, 2009              Portugal                                        Retrospective   24                          1                Mixed                 1,166
  Andrikos et al, 2009            Italy and Greece                                Prospective     4                           22               Mixed                 1,076
  Cartin-Ceba et al, 2009         USA                                             Retrospective   42                          3                Mixed                 11,644
  Costantini et al, 2009          USA                                             Retrospective   36                          1                Surgery               571
  Joannidis et al, 2009           Austria and Portugal                            Prospective     . . .                       303              Mixed                 16,784
  Thakar et al, 2009              USA                                             Retrospective   60                          191              Mixed                 325,395
  Aldawood et al, 2010            Saudi Arabia                                    Retrospective   72                          1                Mixed                 7,173
  Cruz et al, 2010                USA                                             Prospective     6                           1                Mixed                 301
  Elseviers et al, 2010           Belgium                                         Prospective     35                          9                Mixed                 1,303
  Park et al, 2010                Korea                                           Retrospective   6                           1                Mixed                 378
  Clec\'h et al, 2011             France                                          Retrospective   149                         13               Mixed                 8,639
  Darmon et al, 2011              France                                          Prospective     5                           3                Mixed                 203
  Garzotto et al, 2011            Italy                                           Prospective     7                           10               Mixed                 576
  Macedo et al, 2011              USA                                             Prospective     2                           1                Mixed                 75
  Macedo et al, 2011              USA                                             Prospective     . . .                       1                Mixed                 317
  Mandelbaum et al, 2011          USA                                             Retrospective   72                          7                Mixed                 14,524
  Medve et al, 2011               Hungary                                         Prospective     2                           7                Mixed                 459
  Ostermann et al, 2011           England and Germany                             Retrospective   123                         22               Mixed                 22,303
  Piccini et al, 2011             Italy                                           Prospective     7                           10               Mixed                 576
  Prowle et al, 2011              Australia, Canada, Japan, USA, Germany, Italy   Prospective     1                           7                Mixed                 239
  Clark et al, 2012               Canada                                          Prospective     11                          11               Mixed                 119
  Han et al, 2012                 Korea                                           Retrospective   57                          1                Mixed                 1625
  Medve et al, 2012               Hungary                                         Prospective     . . .                       1                Surgery               265
  Odutayo et al, 2012             Canada                                          Prospective     12                          5                Mixed                 603
  Shashaty et al, 2012            USA                                             Retrospective   45                          1                Trauma                400
  Sigurdsson et al, 2012          Iceland                                         Retrospective   12                          2                Mixed                 1012
  Vaara et al, 2012               Finland                                         Retrospective   23                          9                Mixed                 30,380
  Wohlauer et al, 2012            USA                                             Prospective     192                         1                Surgery               2,158
  Allegretti et al, 2013          USA                                             Retrospective   44                          1                Mixed                 863
  Alsultan et al, 2013            Saudi Arabia                                    Prospective     36                          2                Mixed                 2,574
  Fuchs et al, 2013               USA                                             Retrospective   80                          1                Mixed                 12,339
  Legrand et al, 2013             France                                          Retrospective   48                          1                Surgery               137
  Nisula et al, 2013              Finland                                         Prospective     6                           10               Mixed                 1568
  Poukkanen et al, 2013           Finland                                         Prospective     5                           1                Infectious diseases   423
  Poukkanen et al, 2013           Finland                                         Prospective     5                           1                Infectious diseases   918
  Doi et al, 2014                 Japan                                           Prospective     5                           1                Mixed                 339
  Han et al, 2014                 Korea                                           Retrospective   72                          1                Mixed                 1,883
  Linder et al, 2014              Canada                                          Prospective     108                         1                Mixed                 1,844
  Shinjo et al, 2014              Japan                                           Retrospective   60                          1                Mixed                 2,579
  Udy et al, 2014                 Australia, Singapore, Hong Kong and Portugal    Prospective     . . .                       4                Mixed                 281
  Bouchard et al, 2015            Various                                         Prospective     20                          9                Mixed                 316
  Harris et al, 2015              USA                                             Retrospective   12                          1                Surgery               624
  Rimes-Stigiare et al, 2015      Sweden                                          Prospective     72                          41               Mixed                 97,782
  Vanmassenhove et al, 2015       Belgium                                         Prospective     14                          1                Mixed                 195

10.1371/journal.pone.0226325.t003

###### Country and study features description---developing countries.
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  Author                           Home country   Study type      Length of data collection   Number of ICUs   Type of ICU           Number of patients
  -------------------------------- -------------- --------------- --------------------------- ---------------- --------------------- --------------------
  Mataloun et al, 2006             Brazil         Prospective     12                          1                Mixed                 221
  Silva Junior et al, 2006         Brazil         Retrospective   48                          1                Mixed                 381
  Chow et al, 2007                 Malaysia       Prospective     6                           1                Mixed                 18,697
  Daher et al, 2008                Brazil         Retrospective   36                          1                Infectious diseases   722
  Lima et al, 2008                 Brazil         Retrospective   36                          1                Infectious diseases   829
  Fernandes et al, 2009            Brazil         Prospective     10                          1                Mixed                 89
  Friedericksen et al, 2009        South Africa   Retrospective   12                          1                Mixed                 198
  Chang et al, 2010                Taiwan         Retrospective   35                          1                Mixed                 291
  Maccariello et al, 2010          Brazil         Prospective     18                          11               Mixed                 244
  Balushi et al, 2011              Oman           Retrospective   12                          1                Mixed                 1,373
  Ponce et al, 2011                Brazil         Prospective     24                          1                Mixed                 564
  Fonseca Ruiz et al, 2011         Colombia       Retrospective   24                          1                Mixed                 794
  Samimagham et al, 2011           Iran           Retrospective   12                          1                Mixed                 235
  Alves et al, 2012                Brazil         Retrospective   15                          1                Mixed                 204
  Chen et al, 2012                 Taiwan         Prospective     12                          1                Mixed                 150
  Daher et al, 2012                Brazil         Prospective     12                          1                Mixed                 408
  Lai et al, 2012                  Taiwan         Retrospective   101                         1                Surgical              634
  Wahrhaftig et al, 2012           Brazil         Prospective     12                          1                Mixed                 200
  Zhou et al, 2012                 China          Retrospective   8                           5                Mixed                 1,036
  Dalboni et al, 2013              Brazil         Prospective     . . .                       1                Mixed                 303
  Levi et al, 2013                 Brazil         Prospective     12                          1                Mixed                 190
  Silva et al, 2013                Brazil         Prospective     20                          6                Mixed                 366
  Singh et al, 2013                India          Prospective     17                          1                Mixed                 1,504
  Daher et al, 2014                Brazil         Retrospective   99                          1                Infectious diseases   253
  Luo et al, 2014                  China          Prospective     6                           30               Mixed                 3,107
  Morales-Buenrostro et al, 2014   Mexico         Prospective     3                           1                Mixed                 56
  Peng et al, 2014                 China          Retrospective   36                          1                Infectious diseases   211
  Wijewickrama et al, 2014         Sri Lanka      Prospective     6                           1                Mixed                 108
  Bentata et al, 2015              Morocco        Retrospective   84                          1                Obstetric             186
  Bouchard et al, 2015             Various        Prospective     20                          5                Mixed                 429
  Heegard et al, 2015              Afghanistan    Prospective     18                          2                Trauma                134
  Ralib et al, 2015                Malaysia       Prospective     3                           1                Mixed                 143
  Santos et al, 2015               Brazil         Prospective     12                          1                Mixed                 279

The 92 studies report data from 1,091,871 patients. The number of patients from developed countries was 30 times higher; 1,057,332 vs. 34,539 patients in developed versus developing countries, respectively. Larger cohorts with more than 5,000 patients were more frequent in developed countries \[33.3% (20/60)\], whereas in developing countries, 87.8% (29/33) of the studies included less than 1,000 patients (Tables [2](#pone.0226325.t002){ref-type="table"} and [3](#pone.0226325.t003){ref-type="table"}). The number of ICUs included in developed countries was significantly higher than in developing countries (990 vs. 86 ICUs). In fact, in developed countries, 41.6% of the studies (25/60) assessed more than five ICUs, while in developing countries, 81.8% of studies (27/33) assessed only one ICU. The majority of studies (82.7%, i.e., 77/93) evaluated patients from ICUs classified as \"mixed\" (Tables [2](#pone.0226325.t002){ref-type="table"} and [3](#pone.0226325.t003){ref-type="table"}).

### Definition of AKI {#sec014}

Both developed and developing country studies frequently used RIFLE, AKIN, KDIGO, as defined or modified ([Fig 2](#pone.0226325.g002){ref-type="fig"}). In developed countries, AKIN and RIFLE were the most frequently used criteria \[37.9% (22/58) and 34.4%, (20/58), respectively\], followed by increased SCr (24.1%, 14/58). In developing countries, RIFLE and AKIN were also more often applied \[39.3% (13/33) and 33.3% (11/33), respectively\], followed by KDIGO at 21.2% (7/33) (Tables [4](#pone.0226325.t004){ref-type="table"} and [5](#pone.0226325.t005){ref-type="table"}). The majority of studies \[73.2% (41/56) in developed countries and 78.1% (25/32) in developing countries\] reported using both increases in SCr and decreases in urinary volume for the AKI diagnosis.

![Flowchart of AKI definition criteria.\
Footnote: 1 One study contained data from both (developed and developing) country groups, and the respective data were included in each country group for the analysis. 2 Two studies did not mention the criteria used for the definition of IRA.](pone.0226325.g002){#pone.0226325.g002}

10.1371/journal.pone.0226325.t004

###### AKI characteristics---developed countries.
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  Author                          AKI Frequency (%)   AKI definition                  Criteria used for AKI definition   Timeframe for AKI assessment                                  Oliguric patients (%)   Oliguria definition     Reference creatinine definition
  ------------------------------- ------------------- ------------------------------- ---------------------------------- ------------------------------------------------------------- ----------------------- ----------------------- ---------------------------------------------------------------------------------
  Abosaif et al, 2005             . . .               RIFLE                           Cr                                 . . .                                                         . . .                   \< 0.5 ml/kg/h x 6 h    Lower Cr on hospital admission
  Bagshaw et al, 2005             4.2                 Cr rise/Oliguria                Cr/Diuresis                        . . .                                                         77.0                    \< 500 ml x 24 h        . . .
  Chawla et al, 2005              18.0                Cr rise/Oliguria                Cr/Diuresis                        Since ICU discharge or death                                  . . .                   \< 0.5 ml/kg/h x 48 h   . . .
  Ostermann et al, 2005           17.9                Cr rise/Oliguria                Cr/Diuresis                        . . .                                                         . . .                   BUN \> 8 mmol/l         Cr \> 120 mmol/l
  Ahlstrom et al, 2006            51.9                RIFLE                           Cr                                 Since ICU discharge or death                                  . . .                   \< 0.5 ml/kg/h x 6 h    MDRD
  Herrera-Gutiérrez et al, 2006   5.7                 Cr rise/Oliguria                Cr/Diuresis                        . . .                                                         . . .                   \< 400 ml x 24 h        . . .
  Hoste et al, 2006               67.0                RIFLE                           Cr/Diuresis                        . . .                                                         . . .                   \< 0.5 ml/kg/h x 6 h    Lower Cr on hospital admission, or MDRD
  Bagshaw et al, 2007             5.2                 Cr rise/Oliguria                Cr/Diuresis                        . . .                                                         . . .                   . . .                   . . .
  Cruz et al, 2007                10.8                RIFLE                           Cr/Diuresis                        Since ICU discharge or death                                  . . .                   \< 0.5 ml/kg/h x 6 h    MDRD
  Eachempati et al, 2007          6.2                 Cr rise                         Cr                                                                                               . . .                   . . .                   Cr \> 2.4 mg/dl
  Ostermann et al, 2007           35.8                RIFLE                           Cr                                 Since ICU discharge or death                                  . . .                   \< 0.5 ml/kg/h x 6 h    . . .
  Bagshaw et al, 2008             36.1                RIFLE modified                  Cr/Diuresis                        Since ICU discharge or death, after 24 h from ICU admission   . . .                   \< 35 ml/kg/h           MDRD
  Bagshaw et al, 2008             36.1/37.1           RIFLE modified/AKIN modified    Cr/Diuresis                        Since ICU discharge or death, after 24 h from ICU admission   . . .                   \< 35 ml/kg/h           MDRD
  Barrantes et al, 2008           42.9                AKIN                            Cr/Diuresis                        . . .                                                         . . .                   \< 0.5 ml/kg/h x 6 h    . . .
  Lopes et al, 2008               43.8/50.4           RIFLE modified/AKIN modified    Cr/Diuresis                        Until 48 h                                                    . . .                   \< 7.2 ml/kg X 24 h     MDRD
  Ostermann et al, 2008           35.4                Cr rise                         Cr                                 . . .                                                         . . .                   . . .                   . . .
  Abelha et al, 2009              7.5                 AKIN                            Cr/Diuresis                        . . .                                                         . . .                   \< 0.5 ml/kg/h x 6 h    . . .
  Andrikos et al, 2009            16.0                RIFLE                           Cr/Diuresis                        . . .                                                         . . .                   \< 0.5 ml/kg/h x 6 h    . . .
  Cartin-Ceba et al, 2009         50.0                RIFLE                           Cr/Diuresis                        Since ICU discharge or death                                  . . .                   \< 0.5 ml/kg/h x 6 h    Lower Cr 3 months before ICU admission
  Costantini et al, 2009          29.8                AKIN                            Cr/Diuresis                        Since ICU discharge or death after 48 h from admission        . . .                   \< 0.5 ml/kg/h x 6 h    . . .
  Joannidis et al, 2009           35.5/28.5           RIFLE/AKIN                      Cr/Diuresis                        7 days                                                        . . .                   \< 0.5 ml/kg/h x 6 h    MDRD
  Thakar et al, 2009              60.8                AKIN modified                   Cr                                 Since ICU discharge or death                                  . . .                   . . .                   Lower Cr 24 h before hospital admission
  Aldawood et al, 2010            24.4                . . .                           . . .                              Since hospital discharge or death                             . . .                   . . .                   . . .
  Cruz et al, 2010                44.0                Cr rise                         Cr/Diuresis                        . . .                                                         . . .                   \< 0.5 ml/kg/h x 6 h    Lower Cr 3 months before ICU admission or MDRD
  Elseviers et al, 2010           . . .               Cr rise                         Cr                                 . . .                                                         . . .                   . . .                   . . .
  Park et al, 2010                41.3                RIFLE                           Cr/Diuresis                        7 days                                                        . . .                   \< 0.5 ml/kg/h x 6 h    Lower Cr 3 months before hospital admission, or MDRD
  Clec'h et al, 2011              32.9                RIFLE                           Cr/Diuresis                        Since ICU discharge or death                                  . . .                   \< 0.5 ml/kg/h x 6 h    MDRD
  Darmon et al, 2011              67.0                AKIN                            Cr/Diuresis                        12 hours                                                      . . .                   \< 0.5 ml/kg/h x 6 h    . . .
  Garzotto et al, 2011            42.7                RIFLE                           Cr/Diuresis                        . . .                                                         . . .                   \< 0.5 ml/kg/h x 6 h    Lower Cr 3 months before ICU admission
  Macedo et al, 2011              60.0                AKIN                            Cr/Diuresis                        Since ICU discharge or death                                  55.0                    \< 0.5 ml/kg/h x 6 h    First Cr on ICU admission
  Macedo et al, 2011              52.0                AKIN                            Cr/Diuresis                        Since hospital discharge or death                             47.0                    \< 0.5 ml/kg/h x 6 h    First Cr on ICU admission
  Mandelbaum et al, 2011          57.0                AKIN                            Cr/Diuresis                        Since ICU discharge or death                                  . . .                   \< 0.5 ml/kg/h x 6 h    . . .
  Medve et al, 2011               24.4                AKIN                            Cr/Diuresis                        Since ICU discharge or death                                  . . .                   \< 0.5 ml/kg/h x 6 h    First Cr on ICU admission
  Ostermann et al, 2011           35.4                AKIN                            Cr/Diuresis                        Since ICU discharge or death                                  . . .                   . . .                   First Cr on ICU admission
  Piccini et al, 2011             42.7                RIFLE                           Cr/Diuresis                        Since ICU discharge or death                                  . . .                   \< 0.5 ml/kg/h x 6 h    Lowest Cr 3 months before ICU admission
  Prowle et al, 2011              9.6                 AKIN modified/ RIFLE modified   Cr/Diuresis                        4 weeks                                                       38.0                    \< 0.5 ml/kg            Cr before disease or estimated using GRF 75 ml/min
  Clark et al, 2012               7.8                 AKIN                            Cr                                 . . .                                                         . . .                   \< 0.5 ml/kg/h x 6 h    Newest Cr 6 months before ICU admission, or MDRD
  Han et al, 2012                 57.0                AKIN                            Cr/Diuresis                        7 days                                                        . . .                   \< 0.5 ml/kg/h x 6 h    Lowest Cr 7 days before hospital admission
  Medve et al, 2012               18.1                AKIN                            Cr/Diuresis                        . . .                                                         . . .                   \< 0.5 ml/kg/h x 6 h    First Cr on ICU admission
  Odutayo et al, 2012             26.7                AKIN                            Cr                                 90 days                                                       . . .                   \< 0.5 ml/kg/h x 6 h    First Cr on ICU admission
  Shashaty et al, 2012            36.8                AKIN                            Cr/Diuresis                        5 days                                                        . . .                   \< 0.5 ml/kg/h x 6 h    First Cr on ICU admission
  Sigurdsson et al, 2012          21.7                RIFLE                           . . .                              . . .                                                         . . .                   \< 0.5 ml/kg/h x 6 h    Cr 1 year before ICU admission or the lowest after hospital discharge or MDRD
  Vaara et al, 2012               26.6                RIFLE                           Cr                                 Since ICU discharge or death                                  . . .                   \< 0.5 ml/kg/h x 6 h    Lowest Cr during ICU stay
  Wohlauer et al, 2012            2.1                 Cr rise                         Cr                                 Since hospital discharge or death                             . . .                   . . .                   . . .
  Allegretti et al, 2013          . . .               Cr rise                         Cr                                 . . .                                                         . . .                   . . .                   First Cr on ICU admission
  Alsultan et al, 2013            65.0                . . .                           . . .                              . . .                                                         . . .                   . . .                   . . .
  Fuchs et al, 2013               54.3                AKIN                            Cr/Diuresis                        . . .                                                         . . .                   \< 0.5 ml/kg/h x 6 h    Lowest Cr on hospital admission
  Legrand et al, 2013             50.3                AKIN                            Cr/Diuresis                        5 days                                                        . . .                   \< 0.5 ml/kg/h x 6 h    Lowest Cr before ICU admission (time not informed), or MDRD
  Nisula et al, 2013              40,5                KDIGO                           Cr/Diuresis                        5 days after 24 h from admission                              . . .                   \< 0.5 ml/kg/h x 6 h    Newest Cr from last year, excluding the last week before ICU admission, or MDRD
  Poukkanen et al, 2013           36.2                KDIGO                           Cr/Diuresis                        5 days                                                        . . .                   \< 0.5 ml/kg/h x 6 h    Newest Cr from last year, excluding the week before ICU admission
  Poukkanen et al, 2013           53.2                KDIGO                           Cr/Diuresis                        5 days                                                        . . .                   \< 0.5 ml/kg/h x 6 h    Lowest Cr 1 year before ICU admission
  Doi et al, 2014                 38.6                RIFLE                           Cr                                 . . .                                                         . . .                   \< 0.5 ml/kg/h x 6 h    Lowest Cr 3 months before ICU admission or MDRD
  Han et al, 2014                 78.7                KDIGO                           Cr/Diuresis                        . . .                                                         31.8                    \< 0.5 ml/kg/h x 6 h    . . .
  Linder et al, 2014              57.0                KDIGO                           Cr/Diuresis                        Since ICU discharge or death                                  . . .                   \< 0.5 ml/kg/h x 6 h    Lowest Cr 3 months before ICU admission
  Shinjo et al, 2014              29.5/38.4           AKIN/KDIGO                      Cr/Diuresis                        . . .                                                         . . .                   \< 0.5 ml/kg/h x 6 h    Lowest Cr 3 months before ICU admission
  Udy et al, 2014                 65.1                Cr rise                         Cr/Diuresis                        Since ICU discharge or death, after 48 h from admission       . . .                   . . .                   . . .
  Bouchard et al, 2015            19.1                AKIN                            Cr/Diuresis                        7 days                                                        31.5                    \< 0.5 ml/kg/h x 6 h    Cr from 3 to 12 months before ICU admission
  Harris et al, 2015              47.0                RIFLE                           Cr                                 . . .                                                         . . .                   \< 0.5 ml/kg/h x 6 h    Lowest Cr 1 year before ICU admission or MDRD
  Rimes-Stigiare et al, 2015      5.4                 Cr/Oliguria                     Cr/Diuresis                        . . .                                                         . . .                   \< 400 ml x 24 h        . . .
  Vanmassenhove et al, 2015       63.0                Cr rise                         Cr                                 . . .                                                         . . .                   . . .                   MDRD

\* Cr = serum creatinine

10.1371/journal.pone.0226325.t005

###### AKI characteristics---developing countries.
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  Author                           AKI Frequency (%)   AKI definition                 Criteria used for AKI definition   Timeframe for AKI assessment                                   Oliguric patients (%)   Oliguria definition    Reference creatinine definition
  -------------------------------- ------------------- ------------------------------ ---------------------------------- -------------------------------------------------------------- ----------------------- ---------------------- ---------------------------------------------------
  Mataloun et al, 2006             19.0                Cr rise                        Cr                                 Since ICU discharge or death                                   . . .                   . . .                  . . .
  Silva Junior et al, 2006         33.5                Cr rise                        Cr                                 . . .                                                          . . .                   \< 600 ml x 24 h       . . .
  Chow et al, 2007                 1.1                 Oliguria                       Diuresis                           . . .                                                          . . .                   \< 400 ml x 24 h       
  Daher et al, 2008                20.3                RIFLE modified                 Cr/Diuresis                        Since ICU discharge or death                                   34.0                    \< 400 ml x 24 h       Lowest Cr on hospital admission, or MDRD
  Lima et al, 2008                 17.7                RIFLE                          Cr/Diuresis                        Since ICU discharge or death                                   . . .                   \< 0.5 ml/kg/h x 6 h   . . .
  Fernandes et al, 2009            . . .               ATN-ISS                        Diuresis                           Since ICU discharge or death                                   62.0                    \< 400 ml x 24 h       Lowest Cr on hospital admission
  Friedericksen et al, 2009        23.2                Cr rise                        Cr                                 . . .                                                          50.0                    \< 400 ml x 24 h       Lowest Cr on hospital admission
  Chang et al, 2010                . . .               RIFLE/AKIN                     Cr/Diuresis                        . . .                                                          . . .                   \< 0.5 ml/kg/h x 6 h   . . .
  Maccariello et al, 2010          39.8                RIFLE                          Cr/Diuresis                        . . .                                                          . . .                   \< 0.5 ml/kg/h x 6 h   . . .
  Balushi et al, 2011              0.5                 Cr / Oliguria                  Cr/Diuresis                        . . .                                                          . . .                   \< 500 ml x 24 h       . . .
  Ponce et al, 2011                25.5                AKIN                           Cr/Diuresis                        Since ICU discharge or death                                   68.5                    \< 0.5 ml/kg/h x 6 h   . . .
  Fonseca Ruiz et al, 2011         31.1                AKIN                           Cr/Diuresis                        Since ICU discharge or death                                   . . .                   \< 0.5 ml/kg/h x 6 h   . . .
  Samimagham et al, 2011           31.1                AKIN                           Cr/Diuresis                        Since ICU discharge or death                                   . . .                   \< 0.5 ml/kg/h x 6 h   . . .
  Alves et al, 2012                11.8                RIFLE modified/AKIN modified   Cr/Diuresis                        Since ICU discharge or death                                   . . .                   \< 400 ml x 6 h        Last Cr 6 months before ICU admission or MDRD
  Chen et al, 2012                 28.7                AKIN                           Cr/Diuresis                        . . .                                                          . . .                   \< 0.5 ml/kg/h x 6 h   Cr on hospital admission
  Daher et al, 2012                15.3                RIFLE modified                 Cr/Diuresis                        Since ICU discharge or death, after 24 h from admission        . . .                   \< 400 ml x 24 h       Lowest Cr before hospital admission or MDRD
  Lai et al, 2012                  . . .               RIFLE                          Cr/Diuresis                        Since ICU discharge or death                                   . . .                   \< 0.5 ml/kg/h x 6 h   Last Cr within 1 month to 1 year before admission
  Wahrhaftig et al, 2012           36.0                RIFLE modified                 Cr/Diuresis                        Since ICU discharge or death                                   . . .                   \< 0.5 ml/kg/h x 6 h   Lowest Cr before hospital admission or MDRD
  Zhou et al, 2012                 34.1                AKIN                           Cr/Diuresis                        . . .                                                          . . .                   \< 0.5 ml/kg/h x 6 h   Lowest Cr 2 days before ICU admission
  Dalboni et al, 2013              45.6                RIFLE                          Cr                                 48 h                                                           . . .                   \< 0.5 ml/kg/h x 6 h   First Cr on ICU admission
  Levi et al, 2013                 . . .               KDIGO                          Cr/Diuresis                        Since ICU discharge or death, after 24 h from admission        . . .                   \< 0.5 ml/kg/h x 6 h   . . .
  Silva et al, 2013                13.3                RIFLE                          Cr                                 Since ICU discharge or death, after 48 h from admission        . . .                   \< 0.5 ml/kg/h x 6 h   . . .
  Singh et al, 2013                2.2                 RIFLE modified                 Cr/Diuresis                        Since hospital discharge or death, after 48 h from admission   61.0                    \< 400 ml x 24 h       Lowest Cr on hospital admission
  Daher et al, 2014                . . .               RIFLE modified                 Cr/Diuresis                        Since ICU discharge or death                                   . . .                   \< 400 ml x 24 h       Lowest Cr before hospital admission or MDRD
  Luo et al, 2014                  46.9/38.4/51        RIFLE/AKIN/KDIGO               Cr/Diuresis                        10 days                                                        . . .                   \< 0.5 ml/kg/h x 6 h   Lower Cr 3 month before ICU admission
  Morales-Buenrostro et al, 2014   30.3                AKIN                                                              30 days                                                        . . .                   \< 0.5 ml/kg/h x 6 h   First Cr on ICU admission
  Peng et al, 2014                 47.9                KDIGO                          Cr/Diuresis                        . . .                                                          . . .                   \< 0.5 ml/kg/h x 6 h   . . .
  Wijewickrama et al, 2014         60.2                AKIN                           Cr/Diuresis                        . . .                                                          . . .                   \< 0.5 ml/kg/h x 6 h   . . .
  Bentata et al, 2015              34.4                KDIGO                          Cr/Diuresis                        30 days                                                        17.4                    \< 0.5 ml/kg/h x 6 h   First Cr on ICU admission
  Bouchard et al, 2015             19.9                AKIN                           Cr/Diuresis                        7 days                                                         26.1                    \< 0.5 ml/kg/h x 6 h   Cr from 3 to 12 months before hospital admission
  Heegard et al, 2015              34.3                KDIGO                          Cr/Diuresis                        14 days                                                        . . .                   \< 0.5 ml/kg/h x 6 h   Cr 1 year before hospital admission or MDRD
  Ralib et al, 2015                65.0                KDIGO                          Cr/Diuresis                        Since ICU discharge or death, after 48 h from admission        61.0                    \< 0.5 ml/kg/h x 6 h   First Cr on ICU admission, or MDRD
  Santos et al, 2015               32.9                KDIGO                          Cr/Diuresis                        . . .                                                          . . .                   \< 0.5 ml/kg/h x 6 h   Lowest Cr before hospital admission

\* Cr = serum creatinine

### Oliguria definition {#sec015}

Although the oliguria criteria were reported in the majority of the studies, only 10% of developed and 21.2% of developing country studies reported the frequency of oliguric patients.

The oliguria definition was stated in 81.6% (49/60) of developed country studies and in 97% (32/33) of developing country studies. In five studies from developed countries and two from developing countries, the oliguria definition was not available in the manuscript and was obtained through contact with the researcher by electronic mail. In total, 11 different definitions for oliguria were used. The most frequent was "urinary volume \< 0.5 ml/kg/h for 6 h", which was found in 81.6% (40/49) of developed and in 68.7% (22/32) of developing country studies (Tables [4](#pone.0226325.t004){ref-type="table"} and [5](#pone.0226325.t005){ref-type="table"} and [Fig 2](#pone.0226325.g002){ref-type="fig"}).

### Reference serum creatinine definition {#sec016}

The reference SCr definition was available in 68.3% (41/60) of studies in developed countries and 57.5% (19/33) in developing countries. In 12 studies from developed countries and 8 from developing countries, this information was not available in the manuscript, and it was obtained through contact with the researcher. We found 29 different definitions for reference SCr (Tables [4](#pone.0226325.t004){ref-type="table"} and [5](#pone.0226325.t005){ref-type="table"} and [Fig 2](#pone.0226325.g002){ref-type="fig"}), and there was no particular dominant definition.

Timeframe for AKI assessment {#sec017}
----------------------------

The timeframe for AKI diagnosis was available in 58.3% (35/60) of studies in developed countries and 69.6% (23/33) in developing countries. Among those reporting this information, the most used definition for timeframe was "*until ICU discharge or death*" found in 42.8% (15/35) of developed and in 39.1% (9/23) of developing country studies (Tables [4](#pone.0226325.t004){ref-type="table"} and [5](#pone.0226325.t005){ref-type="table"}).

Incidence and AKI etiology {#sec018}
--------------------------

The incidence of AKI was reported in 91.3% (85/93) of the analyzed studies (Tables [4](#pone.0226325.t004){ref-type="table"} and [5](#pone.0226325.t005){ref-type="table"}). Most studies of both developed (54.7%, 29/53) and developing countries (82.1%, 23/28) reported an AKI incidence up to 40%. According to different AKI definitions, AKI incidence varied from 2.1% \[[@pone.0226325.ref012]\] to 78.7% \[[@pone.0226325.ref013]\] in developed countries and from 0.5% \[[@pone.0226325.ref014]\] to 65% \[[@pone.0226325.ref015]\] in developing countries.

AKI etiology was described in 46.6% (28/60) of studies from developed countries and in 66.6% (22/33) of studies from developing countries. Sepsis and shock were the most common causes of AKI in both developed and developing countries (see Tables [6](#pone.0226325.t006){ref-type="table"} and [7](#pone.0226325.t007){ref-type="table"}). The frequency of sepsis as the cause of AKI in developed countries ranged from 4.4% \[[@pone.0226325.ref013]\] to 100% \[[@pone.0226325.ref016]\], and half of the studies had frequencies greater than 40% (9/18). In developing countries, the frequency of sepsis as a cause of AKI ranged from 2.9% \[[@pone.0226325.ref017]\] to 100% \[[@pone.0226325.ref018]\], and 66.7% of the studies reported a frequency greater than 40% (12/18). In developed countries, shock was less frequently reported as a cause of AKI than in developing countries. Only one study reported tropical diseases (leptospirosis) as contributing to AKI etiology (Tables [6](#pone.0226325.t006){ref-type="table"} and [7](#pone.0226325.t007){ref-type="table"}).

10.1371/journal.pone.0226325.t006

###### Characteristics of patients with AKI---developed countries.

![](pone.0226325.t006){#pone.0226325.t006g}

  Author                          Median age   Male gender (%)   AKI etiology                                                           Comorbidities                                        Patient location before ICU                                   Severity scores
  ------------------------------- ------------ ----------------- ---------------------------------------------------------------------- ---------------------------------------------------- ------------------------------------------------------------- ----------------------------------------
  Abosaif et al, 2005             65           68                Sepsis 41.2%                                                           CVD\* 41.2%, COPD\* 41.2%, CKD\* 48.4%               Surgery room 47.5%, ward 52.5%                                APACHE II 22.3/ SAPS II 51.5
  Bagshaw et al, 2005             65           62                Shock 15%, drugs 85%                                                   CVD 50%, COPD 34.6%, DM\* 30%, CKD 18.8%             . . .                                                         APACHE II 33
  Chawla et al, 2005              65           54                . . .                                                                  CVD 30.4%, DM 36.6%, CKD 18%                         . . .                                                         APACHE II 12.5
  Ostermann et al, 2005           61           64                Surgery 59.4%, medical 40.5%                                           . . .                                                Surgery room 57.1%, ward 16.4%, emergency 15.6%               APACHE II 14
  Ahlstrom et al, 2006            63                             . . .                                                                  . . .                                                . . .                                                         APACHE II 22
  Herrera-Gutiérrez et al, 2006   59           71                Shock 36.6%, drugs 38.4%, mixed 21.2%                                  CVD 84.7%, COPD 18%, CKD 4.4%                        Surgery room 18.1%, ward 31.3%, emergency 7.9%                APACHE II 22.5/ SOFA 11.9
  Hoste et al, 2006               63           49                Sepsis 17.2%, heart failure 33%, neurological 20.7%                    . . .                                                Surgery room 61.5%, ward 38.3%                                APACHE II 56 / SOFA 7.8
  Bagshaw et al, 2007             64           61                . . .                                                                  CVD 11.6%, COPD 8.5%, HD\* 4.8%                      Surgery room 49.6%, ward 50.4%                                APACHE II 16.4
  Cruz et al, 2007                64           62                Sepsis 25.6%, shock 38%, drugs 14.5%, contrast 5.6%                    CVD 58.5%, DM 25.6%                                  Surgery room 27,8%, ward 37.2%                                . . .
  Eachempati et al, 2007          63           60                . . .                                                                  . . .                                                Surgery room 100%                                             APACHE III 81
  Ostermann et al, 2007           61           64                . . .                                                                  . . .                                                Surgery room 57.1%, ward 16.4%, emergency 15.6%               APACHE II 21
  Bagshaw et al, 2008             55           16                . . .                                                                  CVD 17.7%, COPD 9.7%, HD 3%                          Emergency 100%                                                APACHE II 20.9/APACHE III 71.7
  Bagshaw et al, 2008             62           60                Sepsis 27.8%                                                           . . .                                                Surgery room 49.7%                                            APACHE II 16.9
  Barrantes et al, 2008           67           57                Sepsis 19.4%, respiratory failure 35.2%                                . . .                                                . . .                                                         APACHE II 15
  Lopes et al, 2008               59           59                . . .                                                                  CVD 53.2%                                            Ward 76.4%, others 23.6%                                      SAPS II 46.3
  Ostermann et al, 2008           61           61                Surgery 45.7%, medical 54.2                                            . . .                                                Surgery room 43.1%, ward 24.2, Emergency 18.6%                APACHE II 18, SOFA 7
  Abelha et al, 2009              64           65                Emergency 33%                                                          CVD 46%                                              Emergency 33%                                                 APACHE II 13, SAPS II 33
  Andrikos et al, 2009            72           67                Sepsis 45.3%, shock 9.4%, Surgery 21.2%, drugs 7.1%                    CVD 67.5%, DM 32.9%                                  Surgery room 31.8%, ward 38.8%, emergency 20%                 . . .
  Cartin-Ceba et al, 2009         66           54                . . .                                                                  . . .                                                . . .                                                         APACHE III 11.5
  Costantini et al, 2009          46           71                Trauma 100%                                                            . . .                                                Emergency 100%                                                . . .
  Joannidis et al, 2009           63           61                post surgery 34.5%, emergency 65.3%                                    CVD 9.1%, COPD 4.2%, DM 8.5%, HD 3.1%                Surgery room 55%, ward 42.2%                                  SOFA 3, SAPS III 47
  Thakar et al, 2009                           98                . . .                                                                  CVD 51.6%, COPD 22.1%, DM 28.6%, CKD 3.6%, HD 4.5%   Surgery room 22%, ward 45%                                    . . .
  Aldawood et al, 2010            60           55                . . .                                                                  . . .                                                Surgery room 3%, ward 84%, others 13%                         APACHE II 33
  Cruz et al, 2010                64           69                . . .                                                                  DM 15.6%, CKD 6.6%                                   Surgery room 8.3%, ward 54.6%, emergency 37.1%                APACHE II 20/ SOFA 5/SAPS II 45
  Elseviers et al, 2010           64           63                Shock 45.5%, drugs 54.5%                                               . . .                                                Surgery room 27.2%, ward 72.8%                                APACHE II 23.9/ SOFA 9.2
  Park et al, 2010                63           63                . . .                                                                  . . .                                                Surgery room 17.5%, ward 82.5%                                SOFA 7.4
  Clec\'h et al, 2011             66           59                . . .                                                                  CVD 17.9%, COPD 12.9%, HD 6.3%, DM 16.4%             Surgery room 10.9%, ward 71.8%, emergency 17.3%               APACHE II 19.9/ SOFA 5.3/ SAPS II 50.2
  Darmon et al, 2011              61           49                Sepsis 67.5%, shock 19.8%, Drugs 20.7%, CKD 16.3%, contrast 8.9%       . . .                                                . . .                                                         SAPS II 46
  Garzotto et al, 2011            66           59                CVD 12.1%, respiratory failure 27.4%, neurological 17%, trauma 14.4%   . . .                                                Surgery room 52.7%, ward 47.3%                                APACHE 18, SOFA 5, SAPS II 43
  Macedo et al, 2011              69           58                Sepsis 47%                                                             CVD 70%, DM 30%, CKD 12%, HD 35%, COPD 2.1%          ...                                                           . . .
  Macedo et al, 2011                           63                Sepsis 18.5%, shock 34.7%, respiratory failure 52%, drugs 18.5%        CVD 31.7%, DM 30.5%, HD 17.3%                        . . .                                                         . . .
  Mandelbaum et al, 2011          66           58                . . .                                                                  . . .                                                . . .                                                         SOFA 5
  Medve et al, 2011               65           56                Sepsis 44%, shock 39%, post operatory 16%, drugs 2%                    . . .                                                Surgery room 64.3%, ward 35.7%,                               SOFA 6/ SAPS II 47.5
  Ostermann et al, 2011           62           63                . . .                                                                  . . .                                                Surgery room 38%, ward 30.7%, emergency 14.1%, others 17.2%   APACHE II 18/ SOFA 7
  Piccini et al, 2011             66           59                CVD 12.1%, respiratory failure 27.4%, neurological 17%, trauma 14.4%   . . .                                                Surgery room 52.7%, ward 47.3%                                APACHE 18, SOFA 5, SAPS II 43
  Prowle et al, 2011                           59                . . .                                                                  . . .                                                Surgery room 47.7%, ward 52.3%                                . . .
  Clark et al, 2012               59           66                . . .                                                                  CVD 55%, COPD 24%, HD 15%, DM 34%                    Surgery room 41%, ward 45%, emergency 14%                     APACHE II 27/SOFA 13.4
  Han et al, 2012                 68           60                Sepsis 4.4%, CVD 36.7%, Tumor 16.9%                                    . . .                                                Ward 97.9%                                                    APACHE II 19.4
  Medve et al, 2012               67                             Sepsis 45.8%                                                           . . .                                                Surgery room 100%                                             SOFA 5/ SAPS II 40
  Odutayo et al, 2012             65           71                . . .                                                                  CVD 55%, DM 32%                                      Ward 86%, emergency 6%, Others 8%                             . . .
  Shashaty et al, 2012            40           74                . . .                                                                  CVD 16.8%, DM 6%                                     Emergency 100%                                                APACHE III 73
  Sigurdsson et al, 2012          59           61                Sepsis 26%, shock 46.4%, respiratory failure 35.4%, surgery 35%        CVD 46%, DM 14%, COPD 25%, HD 3%                     . . .                                                         APACHE II 23
  Vaara et al, 2012               63           63                . . .                                                                  . . .                                                Surgery room 39.7%, ward 36.7%                                SOFA 10/ SAPS II 48
  Wohlauer et al, 2012            37           74                . . .                                                                  . . .                                                Surgery room 100%                                             MOF 184
  Allegretti et al, 2013                       63                . . .                                                                  CVD 29%, DM 29%, COPD 20%, HD 18%                    Surgery room 45%, ward 55%                                    Charlson 2
  Alsultan et al, 2013            54                             . . .                                                                  CVD 22%, DM 20.9%                                    . . .                                                         APACHE II 29.9
  Fuchs et al, 2013               63           60                . . .                                                                  CVD 26%, DM 13%, HD 5%                               Surgery room 24,3%, ward 75.7%                                SOFA 8.9/ SAPS I 16.3
  Legrand et al, 2013             71           60                . . .                                                                  CVD 43%; DM 15%; COPD 9%; HD 7%                      Surgery room 100%                                             SAPS II 57
  Nisula et al, 2013              65           65                . . .                                                                  CVD 77.5%, COPD 10.8%, DM 22.9%, CKD 8.1%            Surgery room 39.4%; emergency 82.1%                           SOFA 9/ SAPS II 42
  Poukkanen et al, 2013           64           92                Sepsis 100%                                                            CVD 19.6%, DM 5.2%                                   Emergency 96.7%                                               SOFA 9, SAPS II 43
  Poukkanen et al, 2013           66           66                Sepsis 31.6%                                                           CVD 10.6%, COPD 12%, DM 24.8%                        Surgery room 24.2%, emergency 97%                             SAPS II 48, SOFA 11
  Doi et al, 2014                 66           61                . . .                                                                  . . .                                                Surgery room 49.6%, ward 50.4%                                APACHE II 15
  Han et al, 2014                 68           60                Sepsis 4.6%, CVD 30.8%, post operatory 1.9%                            DM 12.2%, CKD 8.7%                                   . . .                                                         APACHE II 18.4
  Linder et al, 2014              61           68                Sepsis 81%, post operatory 27.8%                                       CVD 8.1%, COPD 12.7%, DM 2.6%                        . . .                                                         APACHE II 24.6
  Shinjo et al, 2014              63           66                . . .                                                                  CVD 38.5%, DM 18.4%, COPD 3.5%, HD 3.1%              Surgery room 74.3%, ward 13.2%; emergency 12.5%               APACHE II 9/SOFA 4/ SAPS II 28
  Udy et al, 2014                 54           63                . . .                                                                  . . .                                                Surgery room 44.8%, ward 9.3%; emergency 45.9%                IQR 3
  Bouchard et al, 2015            62           62                . . .                                                                  . . .                                                . . .                                                         . . .
  Harris et al, 2015              59           59                . . .                                                                  CVD 46%, DM 26%                                      Surgery room 100%                                             APACHE III 66
  Rimes-Stigiare et al, 2015      68           60                . . .                                                                  . . .                                                . . .                                                         APACHE II 25/ SAPS II 55
  Vanmassenhove et al, 2015       66           67                Sepsis 100%                                                            . . .                                                . . .                                                         APACHE II 27

Neurologic etiologies of AKI include polyuria of diabetes insipidus and salt wasting syndrome; CKD refers to AKI on baseline CKD patients. Comorbidities: CVD = cardiovascular disease DM = diabetes mellitus; COPD = chronic obstructive pulmonary disease; HD = hepatic disease; CKD = chronic kidney disease

10.1371/journal.pone.0226325.t007

###### Characteristics of patients with AKI---developing countries.
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  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                           Median age   Male gender (%)   AKI etiology                               Comorbidities                                Patient location before ICU                                     Severity scores
  -------------------------------- ------------ ----------------- ------------------------------------------ -------------------------------------------- --------------------------------------------------------------- ---------------------------------
  Mataloun et al, 2006             55           46                . . .                                      CVD 35.7%, DM 14%                            Surgery room 44.3%; ward 27.6%; emergency 28.1%                 APACHE II 15.2

  Silva Junior et al, 2006         50           62                Sepsis 40.6%, shock 48.4%, drugs 21.9%     CVD 25.8%, COPD 28.9%                        . . .                                                           . . .

  Chow et al, 2007                 58                             Sepsis 41%, shock 43.6%                    . . .                                        Surgery room 30.8%, ward 69.2%; obstetrics1%                    . . .

  Daher et al, 2008                45           77                Sepsis 41.5%, shock 40.2%, drugs 10.2%     CVD 13%, COPD 19%                            Clinical ward 100%                                              APACHE II 28

  Lima et al, 2008                 45           77                Infection 100%                             CVD 14.2%, HD 40.1%                          . . .                                                           APACHE II 27

  Fernandes et al, 2009            56           62                Sepsis 63%                                 CVD 63%, HD 22%                              Surgery room 44%, ward 51.5%, emergency 45%                     APACHE II 25.5

  Friedericksen et al, 2009        44           61                Sepsis 50%, multiple organ failure 78%     CVD 21.7%, DM 19%                            . . .                                                           APACHE II 23.4

  Chang et al, 2010                62           70                Sepsis 55%                                 DM 27.5%, HD 42%                             . . .                                                           APACHE II 22.8/ SOFA 9.19

  Maccariello et al, 2010          70                             Sepsis 74%, shock 75%, contrast 33%        CVD 68%, DM 28%                              Surgery room 19%, ward 13%; emergency 68%                       SOFA 8.3/ SAPS III 70

  Balushi et al, 2011              61           60                Shock 53.6%, drugs 46.4%                   CVD 53.7%, DM 59.9%                          . . .                                                           . . .

  Ponce et al, 2011                57           56                . . .                                      . . .                                        . . .                                                           . . .

  Fonseca Ruiz et al, 2011         53           53                Sepsis 19.6%                               CVD 44,6%, DM 18,2%                          Surgery room 38.2%, ward 57.6%, emergency 4.2%                  APACHE II 13/SOFA 4/ SAPS II 27

  Samimagham et al, 2011           40           71                . . .                                      . . .                                        Surgery room 52.3%, ward 11.1%                                  APACHE II 23.9

  Alves et al, 2012                50           45                Sepsis 65%                                 . . .                                        Surgery room 27.9%, ward 67.4%\                                 SOFA 9.8
                                                                                                                                                          Obstetrics 4.7%                                                 

  Chen et al, 2012                 69           75                . . .                                      CVD 73%, DM 61%                              Ward 100%                                                       APACHE II 14

  Daher et al, 2012                55                             Sepsis 40%, drugs 14%, leptospirosis 12%   CVD 24,7%; DM 14,8%                          Ward 100%                                                       . . .

  Lai et al, 2012                  64           66                . . .                                      CVD 58.4%, DM 28.7%                          Surgery room 70.7%, emergency 29.3%                             . . .

  Wahrhaftig et al, 2012           66           47                Sepsis 74.2%, shock 17%                    CVD and DM 99%                               Surgery room 13.8%, ward 29.7%, emergency 17.3%, others 35.6%   APACHEII 13 /SOFA 3

  Zhou et al, 2012                 59           69                Sepsis 30.6%, respiratory failure 79.9%    CVD 36%, DM 12.8%                            Surgery room 3.7%, ward 79.1%, emergency 7.6%, other 9.6%       APACHE III 45.4 / SOFA 5.1

  Dalboni et al, 2013              67           66                . . .                                      CVD 39%, DM 18%                              . . .                                                           APACHE II 20

  Levi et al, 2013                 64           45                Sepsis 46.8%, CVD 42%                      CVD 46.8%, DM 32.2%                          Surgery room 30.5%, ward 30.5%, emergency 22.6%                 APACHE II 15

  Silva et al, 2013                57           60                . . .                                      COPD 77,3%, HD 49,2%                         . . .                                                           SAPS III 69.7

  Singh et al, 2013                51           0                 Sepsis 35.2%, shock 14.2%, drugs 23.5%     CVD 13,7%, COPD 23,5%                        . . .                                                           . . .

  Daher et al, 2014                46           72                . . .                                      HIV/AIDS 30%, Tuberculosis 12%               Ward 100%                                                       APACHE II 50

  Luo et al, 2014                  61           65                Sepsis 32.2                                CVD 5.9%, COPD 6.1%, CKD\* 6.1%, DM 18.9%,   Surgery room 57%,                                               SOFA 6

  Morales-Buenrostro et al, 2014   52           54                . . .                                      CVD 16.2%, DM 24.3%                          Surgery room 21.6%, ward 64,9%, others 10.8%                    . . .

  Peng et al, 2014                 52           68                Sepsis 100%                                . . .                                        . . .                                                           APACHE II 20.8

  Wijewickrama et al, 2014         48           62                Sepsis 28.7%, shock 12.1%                  CVD 28%, DM 27%                              . . .                                                           SOFA 9

  Bentata et al, 2015              28                             Obstetrics\                                CVD 19.5%,                                   Emergency 22%                                                   . . .
                                                                  100%                                                                                                                                                    

  Bouchard et al, 2015             59           63                . . .                                      . . .                                        . . .                                                           . . .

  Heegard et al, 2015              26           98                Trauma 100%                                . . .                                        Emergency 100%                                                  . . .

  Ralib et al, 2015                50           64                . . .                                      CVD 36.4%, DM 28.7%                          Surgery room 25.2%, ward 74.8%                                  APACHE II 19.4/ SOFA 8.7

  Santos et al, 2015               43           66                Sepsis 2.9%, CVD 3.2%, emergency 48.4%     DM 12.9%                                     Emergency 48.8%                                                 APACHE II 10
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Comorbidities: CVD = cardiovascular disease; DM = diabetes mellitus; COPD = chronic obstructive pulmonary disease; HD = hepatic disease; CKD = chronic kidney disease

Patient characteristics {#sec019}
-----------------------

### Age {#sec020}

Almost 40% (22/56) of the studies in developed countries described a mean age above 65 years in AKI patients (ranging from 37 \[[@pone.0226325.ref012]\] to 72 years \[[@pone.0226325.ref019]\]), while only 12.1% (4/33) of the studies in developing countries reported an age higher than 65 years in AKI patients (ranging from 26 \[[@pone.0226325.ref020]\] to 70 years \[[@pone.0226325.ref021]\]) (Tables [6](#pone.0226325.t006){ref-type="table"} and [7](#pone.0226325.t007){ref-type="table"}). The weighted mean ages were 62.0 and 56.8 years for developed and developing country patients, respectively.

### Gender and ethnicity {#sec021}

Male sex was predominant in AKI patients in both groups of countries: 59.6% (34/57) and 67.8% (19/28) of the studies in developed and developing countries, respectively, reported a male frequency above 60%. The weighted male frequencies were 67.1% and 64.5% for developed and developing country patients, respectively.

Only 9.5% (9) of the studies reported the patients' ethnic background (Tables [6](#pone.0226325.t006){ref-type="table"} and [7](#pone.0226325.t007){ref-type="table"}).

### Comorbidities {#sec022}

Comorbidities were assessed in 51.6% (31/60) and 78.7% (26/33) of studies from developed and developing countries, respectively. The most prevalent comorbidities were cardiovascular diseases (CVD), diabetes and chronic respiratory disease.

In developed counties, a CVD frequency greater than 40% was reported in 51.6% (16/31), versus 30.4% (7/23) in developing countries. The weighted CVD frequencies were 41.3% and 32.6% for developed and developing country patients, respectively.

The frequency of diabetes was similar in both groups of countries. In approximately 60% (16/27 in studies of developed and 10/18 of developing countries) of studies, the prevalence of diabetes was over 20% in the studied population (Tables [6](#pone.0226325.t006){ref-type="table"} and [7](#pone.0226325.t007){ref-type="table"}). The weighted diabetes frequencies were 27.3% and 24.5% for developed and developing country patients, respectively.

### Severity scores {#sec023}

The most reported severity scores were APACHE II and SOFA. The Apache II score in AKI patients was reported in 32 and 18 studies from developed and developing countries, respectively. The APACHE II score had a similar distribution in the two groups of countries, ranging from 9 \[[@pone.0226325.ref022]\] to 56 \[[@pone.0226325.ref023]\] in developed country studies and from 10 \[[@pone.0226325.ref017]\] to 50 \[[@pone.0226325.ref024]\] in studies from developing countries. Approximately half of the studies had an APACHE II score up to 20 (16/32) in developed and in developing countries (9/18) (Tables [6](#pone.0226325.t006){ref-type="table"} and [7](#pone.0226325.t007){ref-type="table"}). The weighted APACHE II scores were 18.7 and 21.0 for developed and developing country patients, respectively.

The SOFA score was reported in 21 and 10 studies from developed and developing countries, respectively. The distribution of the SOFA score was similar between groups, ranging from 3 \[[@pone.0226325.ref025]\] to 13.4 \[[@pone.0226325.ref026]\] in studies from developed countries and from 3 \[[@pone.0226325.ref027]\] to 9.8 \[[@pone.0226325.ref028]\] in developing country studies. In studies where this information was available, a SOFA score over 5 was reported by 71% (15/21) of studies from developed countries and 80% (8/10) of studies in developing countries (Tables [6](#pone.0226325.t006){ref-type="table"} and [7](#pone.0226325.t007){ref-type="table"}). The weighted SOFA scores were 7.6 and 8.2 for developed and developing country patients, respectively.

### Patient location before ICU {#sec024}

Most of the AKI patients who were admitted to the ICU came from surgical and clinical wards units. The majority of manuscripts from both developed countries (13/16) and developing countries (9/11) reported that up to 50% of patients with AKI had hospital admission in emergency situations (Tables [6](#pone.0226325.t006){ref-type="table"} and [7](#pone.0226325.t007){ref-type="table"}).

Outcomes {#sec025}
--------

### Length of ICU and hospital stay {#sec026}

In developed and in developing countries, 71.6% (43/60) and 69.6% (23/33) of the studies reported the length of ICU stay for AKI patients, which ranged from 1 to 22 days and from 5 to 23 days, respectively. The reported ICU stay was longer than seven days in 38.6% (17/44) and 80% (20/25) of developed and developing country studies, respectively (Tables [8](#pone.0226325.t008){ref-type="table"} and [9](#pone.0226325.t009){ref-type="table"}). The weighted mean ICU stay lengths were 7.2 and 12.2 days for developed and developing country patients, respectively.

10.1371/journal.pone.0226325.t008

###### Outcomes---Developed countries.

![](pone.0226325.t008){#pone.0226325.t008g}

  Autor                           ICU stay (days)   Hospital stay (days)   RRT in ICU AKI patients (%)   Type of RRT        Mortality in ICU AKI patients (%)
  ------------------------------- ----------------- ---------------------- ----------------------------- ------------------ -----------------------------------
  Abosaif et al, 2005             . . .             . . .                  38.8                          C 100%             47.5
  Bagshaw et al, 2005             8.1               22                     6                             C 61%, I 20%       50
  Chawla et al, 2005              . . .             . . .                  37.1                          . . .              
  Ostermann et al, 2005           . . .             . . .                  . . .                         C 92%, I 7.1%      66.7
  Ahlstrom et al, 2006            . . .             . . .                  7                             . . .              16.6
  Herrera-Gutiérrez et al, 2006   15.6              19.9                   38                            . . .              46.8
  Hoste et al, 2006               3                 16                     6                             . . .              
  Bagshaw et al, 2007             4.4               14.2                   . . .                         . . .              
  Cruz et al, 2007                10                . . .                  30.3                          C 50.7%, I 14.1%   36.3
  Eachempati et al, 2007          16                15.9                   19.8                          I 100%             45
  Ostermann et al, 2007           . . .             . . .                  12.2                          C 80.2%, I 5.2%    28.4
  Bagshaw et al, 2008             . . .             . . .                  . . .                         . . .              16.7
  Bagshaw et al, 2008             3.7               14.6                   . . .                         . . .              24.2
  Barrantes et al, 2008           3                 9                      15                            . . .              
  Lopes et al, 2008               8.2               . . .                  27.2                          . . .              41.3
  Ostermann et al, 2008           7                 . . .                  23                            C 93.6%, I 0.4%    31.1
  Abelha et al, 2009              2.8               25                     . . .                         . . .              17.2
  Andrikos et al, 2009            13                . . .                  53.5                          C 86%, I 13.2%     64.7
  Cartin-Ceba et al, 2009         . . .             . . .                  19                            C 39%, I 61%       20
  Costantini et al, 2009          13.6              25                     7                             . . .              15.9
  Joannidis et al, 2009           2.8               . . .                  . . .                         . . .              16
  Thakar et al, 2009              . . .             . . .                  4.4                           . . .              
  Aldawood et al, 2010            15                . . .                  9                             . . .              64
  Cruz et al, 2010                7                 . . .                  . . .                         . . .              17.3
  Elseviers et al, 2010           16.4              34.2                   49.9                          C 42%, I 58%       58
  Park et al, 2010                . . .             17.2                   . . .                         . . .              62.8
  Clec\'h et al, 2011             7                 . . .                  19                            . . .              
  Darmon et al, 2011              . . .             . . .                  22.1                          . . .              36.7
  Garzotto et al, 2011            5                 . . .                  8                             . . .              21.7
  Macedo et al, 2011              4                 8                      6                             . . .              
  Macedo et al, 2011              3                 8                      . . .                         . . .              9.5
  Mandelbaum et al, 2011          7                 16                     . . .                         . . .              12.4
  Medve et al, 2011               4.5               13.5                   15.1                          I 64.8%            39.3
  Ostermann et al, 2011           7                 . . .                  . . .                         . . .              31.1
  Piccini et al, 2011             5                 . . .                  8                             . . .              21.7
  Prowle et al, 2011              . . .             . . .                  39                            . . .              22.5
  Clark et al, 2012               . . .             . . .                  . . .                         C 77%, I 17%       
  Han et al, 2012                 7                 . . .                  17                            . . .              
  Medve et al, 2012               6                 18                     . . .                         . . .              33.3
  Odutayo et al, 2012             . . .             . . .                  11.8                          . . .              
  Shashaty et al, 2012            . . .             . . .                  . . .                         . . .              14.9
  Sigurdsson et al, 2012          17                . . .                  17                            . . .              9
  Vaara et al, 2012               12.5              . . .                  6.8                           . . .              29.1
  Wohlauer et al, 2012            14                . . .                  23                            . . .              
  Allegretti et al, 2013          21                . . .                  . . .                         . . .              60.7
  Alsultan et al, 2013            . . .             . . .                  12                            . . .              
  Fuchs et al, 2013               . . .             . . .                  . . .                         . . .              . . .
  Legrand et al, 2013             9                 . . .                  . . .                         . . .              23
  Nisula et al, 2013              2.8               9                      10.3                          . . .              . . .
  Poukkanen et al, 2013           5.7               16                     8                             . . .              . . .
  Poukkanen et al, 2013           4.2               14                     . . .                         . . .              . . .
  Doi et al, 2014                 5                 . . .                  . . .                         . . .              12
  Han et al, 2014                 22                . . .                  38.4                          . . .              67.4
  Linder et al, 2014              9.1               23.4                   . . .                         . . .              67.1
  Shinjo et al, 2014              1                 31                     . . .                         . . .              7.1
  Udy et al, 2014                 5                 . . .                  . . .                         . . .              14
  Bouchard et al, 2015            5                 11                     15.5                          . . .              27.6
  Harris et al, 2015              4.5               19                     12                            . . .              33
  Rimes-Stigiare et al, 2015      . . .             . . .                  6                             . . .              35
  Vanmassenhoe et al, 2015        12                . . .                  13.8                          . . .              23.1

RRT: renal replacement therapy; C = continuous RRT, I = intermittent RRT

10.1371/journal.pone.0226325.t009

###### Outcomes in developing countries.

![](pone.0226325.t009){#pone.0226325.t009g}

  Autor                            ICU stay (days)   Hospital stay (days)   RRT in ICU AKI patients (%)   Type of dialysis   Mortality in ICU AKI patients (%)
  -------------------------------- ----------------- ---------------------- ----------------------------- ------------------ -----------------------------------
  Mataloun et al, 2006             16.1              . . .                  23.8                          I 100%             76.2
  Silva Junior et al, 2006         17                . . .                  32                            I 100%             62.5
  Chow et al, 2007                 13.7              . . .                  16.7                          P 69.2%, I 15.3%   . . .
  Daher et al, 2008                11                . . .                  35                            I 100%             66.6
  Lima et al, 2008                 12                . . .                  35                            . . .              64.6
  Fernandes et al, 2009            22                22.3                   48                            C 30%, I 10%       85
  Friedericksen et al, 2009        10.8              . . .                  17.3                          C 25%, I 75%       47.8
  Chang et al, 2010                11.4              . . .                  . . .                         . . .              60.8
  Maccariello et al, 2010          23                29                     . . .                         C 84%              63
  Balushi et al, 2011              . . .             . . .                  60.7                          . . .              
  Ponce et al, 2011                12.9              . . .                  . . .                         . . .              62.5
  Fonseca Ruiz et al, 2011         8.4               . . .                  12.4                          C 30.8%, I 69.2%   25.4
  Samimagham et al, 2011           10.6              . . .                  . . .                         . . .              72.6
  Alves et al, 2012                10.7              . . .                  2.3                           I 100%             29
  Chen et al, 2012                 . . .             . . .                  . . .                         . . .              
  Daher et al, 2012                . . .             . . .                  68                            I 100%             33.6
  Lai et al, 2012                  . . .             . . .                  . . .                         . . .              . . .
  Wahrhaftig et al, 2012           12                . . .                                                . . .              53.3
  Zhou et al, 2012                 11.6              . . .                  63.5                          . . .              50
  Dalboni et al, 2013              . . .             . . .                  . . .                         . . .              9
  Levi et al, 2013                 . . .             . . .                  . . .                         . . .              63.1
  Silva et al, 2013                17                20.5                   28.7                          C 85.3%, I 14.7%   78.6
  Singh et al, 2013                . . .             . . .                  20.6                          . . .              73.5
  Daher et al, 2014                . . .             . . .                  27.6                          . . .              62.8
  Luo et al, 2014                  5                 27.4                   . . .                         . . .              . . .
  Morales-Buenrostro et al, 2014   . . .             . . .                  . . .                         . . .              . . .
  Peng et al, 2014                 8.5               15.7                   . . .                         . . .              . . .
  Wijewickrama et al, 2014         11.6              . . .                  58.4                          I 97.3%; P 2.7%    52.3
  Bentata et al, 2015              6.5               . . .                  . . .                         . . .              10.2
  Bouchard et al, 2015             6                 10                     30.2                          . . .              . . .
  Heegard et al, 2015              . . .             . . .                  5.6                           . . .              21.7
  Ralib et al, 2015                6.4               14.2                   25                            C 36%, I 58.3%     91
  Santos et al, 2015               9.5               . . .                  71.7                          . . .              33.3

RRT: renal replacement therapy; C = continuous RRT, I = intermittent RRT; P = peritoneal dialysis

In non-AKI patients, ICU stays longer than 7 days were not reported in developed country studies (0/24) but occurred in 44% (4/9) of studies in developing countries. In developed and developing country studies, 38.3% (23/60) and 21.2% (7/33) of the studies reported the length of hospital stay, which ranged from 8 to 31 days and 10 to 29 days, respectively. Hospital stays were longer than 15 days in 58.3% (14/24) and 66.7% (6/9) of developed and developing country studies, respectively (Tables [8](#pone.0226325.t008){ref-type="table"} and [9](#pone.0226325.t009){ref-type="table"}). In non-AKI patients, the hospital stay was longer than 15 days in 25% (4/16) and 33.3% (1/3) in developed and in developing country studies, respectively. The weighted mean lengths of hospital stay were 15.5 and 23.6 days for developed and developing country patients, respectively.

### Renal replacement therapy {#sec027}

Sixty-three percent of the analyzed studies reported the use of renal replacement therapy (RRT) in ICU AKI patients. In developed countries, 21% of the 38 studies with available data referred to the use of RRT in ICU AKI patients as being greater than 30%. In developing countries, 48% of the 21 studies with available data showed that the frequency of RRT use was higher than 30% in ICU AKI patients (Tables [8](#pone.0226325.t008){ref-type="table"} and [9](#pone.0226325.t009){ref-type="table"}). The weighted frequencies of RRT were 8.8% and 23.8% for developed and developing country patients, respectively.

### Mortality {#sec028}

Reported ICU mortality in AKI patients was greater in developing country studies. AKI mortality greater than 60% was reported in 15.9% (7/44) of studies from developed countries and 56% from developing countries (14/25) (Tables [8](#pone.0226325.t008){ref-type="table"} and [9](#pone.0226325.t009){ref-type="table"}). The weighted frequencies of mortality were 30.8% and 54.8% for developed and developing country patients, respectively.

Synthesis of AKI incidence {#sec029}
--------------------------

Pooled AKI incidence estimates for developed and developing countries in the meta-analysis are presented in [Table 10](#pone.0226325.t010){ref-type="table"}, according to the AKI definition used. The RIFLE, AKIN or KDIGO criteria for AKI definition was used, as defined, by 39 and 21 studies in developed and developing country studies, respectively. One study in developed countries and 3 in developing countries studies did not report AKI incidence, so 38 and 18 studies, respectively, had an AKI incidence estimation included in the meta-analysis. The pooled estimate of AKI incidence in developed and developing countries is shown in [Fig 3](#pone.0226325.g003){ref-type="fig"}. There was a tendency towards a greater incidence in developed countries, although this was not significant. When only prospective studies were analyzed, this tendency disappeared ([Table 10](#pone.0226325.t010){ref-type="table"}).

![Forest plot of AKI incidence.\
Footnote: The studies shown are those that used the RIFLE, AKIN or KDIGO criteria for AKI definition. A) Developed country studies; B) Developing country studies.](pone.0226325.g003){#pone.0226325.g003}

10.1371/journal.pone.0226325.t010

###### Pooled AKI frequency of developed and developing countries' studies according to AKI Definition.

![](pone.0226325.t010){#pone.0226325.t010g}

  Subgroup                                Country group   Studies   Patients   AKI frequency   95% confidence   Test for heterogeneity   
  --------------------------------------- --------------- --------- ---------- --------------- ---------------- ------------------------ -------
  RIFLE/AKIN/KDIGO                        Developed       38        153,846    39.3            34.6--43.9       27.5                     0.062
                                          Developing      18        9,174      35.1            28.4--41.9       -15.1                    0.612
  RIFLE                                   Developed       14        71,954     37.4            30.0--44.8       13.0                     0.018
                                          Developing      4         1,742      26.9            15.3--42.0       26.9                     0.250
  AKIN                                    Developed       18        72,677     36.9            29.5--44.3       22.7                     0.185
                                          Developing      8         3,372      30.8            25.5--36.1       42.2                     0.097
  KDIGO                                   Developed       6         9,215      50.7            38.3--63.1       7.26                     0.370
                                          Developing      6         4,060      43.8            34.7--52.8       15.2                     0.316
  RIFLE/AKIN/KDIGO--Prospective studies   Developed       18        29,164     37.4            30.9--43.9       26.4                     0.145
                                          Developing      13        6,677      36.2            27.4--44.9       -16.2                    0.587

\*Included the studies that used the RIFLE, AKIN or KDIGO definition

[Fig 4](#pone.0226325.g004){ref-type="fig"} shows the funnel plot for both country groups in which individual study frequency of AKI is a function of their sample size with the pooled incidence of studies that used the RIFLE, AKIN or KDIGO criteria for the AKI definition being depicted as a black line. Note that the [Fig 4A](#pone.0226325.g004){ref-type="fig"} (developed countries) had a 10-fold greater sample size than [Fig 4B](#pone.0226325.g004){ref-type="fig"} (developing countries). The studies with a greater sample size depart from the polled estimated AKI incidence, suggesting the possibility of publication bias or bias resulting from the lack of standardizing reference creatinine, oliguria, and the timeframe for AKI assessment.

![Funnel plot of sample size of studies as a function of AKI incidence.\
Footnote: The studies shown are those that used the RIFLE, AKIN or KDIGO criteria for AKI definition. A) Developed country studies; B) Developing country studies. Pooled AKI incidence is depicted as a vertical line.](pone.0226325.g004){#pone.0226325.g004}

Discussion {#sec030}
==========

We found a high incidence of AKI in both country categories, and a tendency towards a greater incidence in developed countries. Due to the differences in AKI definitions, timeframe and the types of studied population, the reported incidence varied from 0.5% to 78%.

Our review covered a 10-year period. Thus, different AKI definitions were used for AKI assessment, including the RIFLE, AKIN and KDIGO criteria \[[@pone.0226325.ref029],[@pone.0226325.ref030],[@pone.0226325.ref031]\]. Only two-thirds of the studies reported the definition for reference serum creatinine, with 29 different definitions used, which results in high heterogeneity of AKI incidence estimate \[[@pone.0226325.ref032]\]. In the most recent AKI definitions (RIFLE, AKIN and KDIGO), the reference SCr is the value observed up to seven days or 48 hours before the SCr increase defining the AKI diagnosis. However, we observed that several studies used as reference SCr values obtained months, or even one year before the AKI episode, which is not consistent with the current AKI definitions. When the reference serum creatinine was not available, the MDRD formula has been used for estimation of the missing SCr value, which is a flawed methodology as it can misdiagnose AKI in CKD patients \[[@pone.0226325.ref012],[@pone.0226325.ref033],[@pone.0226325.ref034]\]. The oliguria definition was more uniform, with recent studies correctly using the RIFLE, AKIN and KDIGO oliguria definitions. The addition of urine output criteria was associated with higher and earlier AKI detection and incidences in critically ill patients \[[@pone.0226325.ref032]\].

Another important caveat to create a valid comparison between developed and developing countries is the striking differences in the number of studies and the sample sizes. Eighty per cent of the world population lives in developing countries, but only one-third of the studies sample reported data from them, with the majority assessing a single center with a relatively small number of patients \[[@pone.0226325.ref035]\]. Moreover, approximately half of the studies from developing countries were from Brazil, and only two were from Africa. On the other hand, approximately 40% of developed country studies assessed more than five centers. The sample size from developed countries studies was more than 30-fold greater compared to those from developing countries. There is a clear underrepresentation of developing countries that is probably caused by a lack of health resources and electronic medical records, as well as difficulty in gathering epidemiological data and, consequently, conducting adequate large observational studies. These studies can be more capable to determine the true burden of a disease than trials and more valuable in assessing the incidence and prevalence of the disease \[[@pone.0226325.ref036]\]. A snapshot of worldwide AKI incidence found more severe AKI presentation in patients from developing countries, which was considered to be due to delay in AKI recognition and treatment, adversely affecting the outcomes \[[@pone.0226325.ref007],[@pone.0226325.ref037]\].

The incidence of AKI development in the ICUs was similar in both types of countries, with a numeric tendency to be greater in developed country studies. When only prospective studies were analysed, this tendency disappeared. Developing and developed countries have very distinct healthcare patterns. In developing countries, deficiencies in health structure, long distance from the community to the hospital and poor transportation systems limit patient access to healthcare. Lack of universal health coverage and insufficient funding for the health system imposes significant cost of treatment for the patients and family, including high cost procedures such as ICU and renal replacement therapy \[[@pone.0226325.ref038]\]. Tropical infectious diseases, animal venoms, natural medicine, abortion and eclampsia are known to be important AKI etiological factors in developing countries \[[@pone.0226325.ref039],[@pone.0226325.ref040]\]; however, their incidence was extremely low in the ICU population. This is likely due to the limited number of ICUs, which are located mostly in larger urban cities, as well as inadequate recognition of high-risk AKI patients in the primary health system. Furthermore, difficulty transporting patients due to geographical and economic issues may contribute to this situation \[[@pone.0226325.ref039]\]. As a consequence, developing country's ICUs reflect tertiary hospitals and university hospitals mostly from an urban population. Thus, patient characteristics were similar in both types of country. Sepsis and shock were the main causes of AKI in both developed and developing countries, but the frequency of sepsis was approximately 50% greater in developing country studies. In developed country studies, AKI patients were older, which likely reflects higher population longevity, better socioeconomic conditions and more structured health services. Overall, cardiovascular diseases were the most frequently reported comorbidity, although they were more frequent in developed country studies.

AKI was associated with poor outcomes, higher length of stay (LOS) and mortality, which is consistent with other studies \[[@pone.0226325.ref041],[@pone.0226325.ref042]\]. In developing country studies, AKI had higher LOS and mortality compared to developed countries, although patients were younger, had less CVD and had similar APACHE II scores. Difficulty accessing health services \[[@pone.0226325.ref039],[@pone.0226325.ref043]\] and lack of infrastructure, including ICU beds and human resources for care of the critically ill in these countries \[[@pone.0226325.ref044],[@pone.0226325.ref045]\], are probably the cause of worse outcomes in such a low resource setting. It is possible that the patients treated in developing countries are transferred to an ICU at a late stage of disease progression and have a reduced change of recovering \[[@pone.0226325.ref045]\]. The finding of higher frequency RRT use in developing countries supports this hypothesis.

This systematic review highlighted important caveats for the comparison between ICU AKI epidemiology in developed and developing countries. The vast majority of studies assessed university tertiary hospitals, limiting the generalizability of the results. Different AKI definitions were used over time, and even when the new AKI criteria were used, there is an important lack of standardization for reference serum creatinine. Most of the studies from developing countries were single center. The number of patients and ICUs assessed in developed country studies was greater than 30-fold and 10-fold higher than in developing countries, respectively, highlighting the underrepresentation of developing countries.

Conclusion {#sec031}
==========

AKI incidence was high in both types of countries. Patient characteristics were mostly similar, but outcomes were worse for patients in developing country studies. Despite patient´s similarities, the non-inclusion of secondary hospitals and the differences in the number of studies and sample sizes exemplify the challenge of comparing developing and developed country AKI epidemiology. The widespread application of AKI definitions has made it possible to compare AKI epidemiology across different settings. However, an effort to standardize reference serum creatinine, oliguria and the timeframe for AKI assessment is crucial. There is an urgent need for larger, prospective, multicenter studies that assess broader populations from developing countries.
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